-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
As of the close of trading on October 20, a total of 62 A-share pharmaceutical companies disclosed their performance in the first three quarters of 2022, with more than 90% of the good news
.
Among them, Kangyuan Pharmaceutical is the first pharmaceutical company to release three quarterly reports, 8 companies such as Huadong Pharmaceutical and Dian Diagnostics are expected to have a net profit of more than 2 billion yuan, and 10 companies such as Northeast Pharmaceutical, Wantai Biologics and Zhaoyan New Drug have doubled
.
Jiuan Medical soared 300 times to become the "growth king", the net profit soared from 50 million yuan to 16 billion yuan, the CXO leading performance soared, and chain giants such as Laobai, Da Shenlin and Yifeng steadily climbed
.
In addition, only 3 companies lost money, compared to 17 in the same period last year
.
It is worth mentioning that in December last year, the Shenzhen Stock Exchange revised the stock listing rules and no longer required companies to disclose quarterly performance forecasts
.
From the perspective of the number of announcements, it decreased by more than 30%
year-on-year.
.
Among them, Kangyuan Pharmaceutical is the first pharmaceutical company to release three quarterly reports, 8 companies such as Huadong Pharmaceutical and Dian Diagnostics are expected to have a net profit of more than 2 billion yuan, and 10 companies such as Northeast Pharmaceutical, Wantai Biologics and Zhaoyan New Drug have doubled
.
Jiuan Medical soared 300 times to become the "growth king", the net profit soared from 50 million yuan to 16 billion yuan, the CXO leading performance soared, and chain giants such as Laobai, Da Shenlin and Yifeng steadily climbed
.
In addition, only 3 companies lost money, compared to 17 in the same period last year
.
It is worth mentioning that in December last year, the Shenzhen Stock Exchange revised the stock listing rules and no longer required companies to disclose quarterly performance forecasts
.
From the perspective of the number of announcements, it decreased by more than 30%
year-on-year.
The performance of A-share pharmaceutical companies in the first three quarters of 2022
The performance of A-share pharmaceutical companies in the first three quarters of 2022 is express
Performance forecast of A-share pharmaceutical companies in the first three quarters of 2022
The main performance data of some A-share pharmaceutical companies in the first three quarters of 2022
Super 9 percent good news! 16 billion net profit pharmaceutical stocks appeared, CXO leading performance soared
From the perspective of the companies that have disclosed the results of the three quarterly reports, more than 90% of them are happy, of which Kangyuan Pharmaceutical is the first pharmaceutical company to release the third quarterly report, 8 companies such as Huadong Pharmaceutical and Dian Diagnostics have a net profit of more than 2 billion yuan, and 10 companies such as Northeast Pharmaceutical, Wantai Biologics and Zhaoyan New Drug have doubled
.
Jiuan Medical soared 300 times to become the "growth king", with a net profit soaring from 50 million yuan to 16 billion yuan, and the CXO leading performance soared
.
In addition, only 3 companies lost money, compared with 17 in the same period last year
.
.
Jiuan Medical soared 300 times to become the "growth king", with a net profit soaring from 50 million yuan to 16 billion yuan, and the CXO leading performance soared
.
In addition, only 3 companies lost money, compared with 17 in the same period last year
.
Jiuan Medical net profit: 16 billion ~ 16.
3 billion yuan year-on-year increase: 31818.
29% ~ 32416.
76%
3 billion yuan year-on-year increase: 31818.
29% ~ 32416.
76%
On October 15, Jiunian Medical released its performance forecast for the first three quarters of 2022, with an expected net profit of 16 billion ~ 16.
3 billion yuan, a year-on-year increase of 31818.
29% ~ 32416.
76%, only 50.
13 million yuan
in the same period last year.
Jiuan Medical said that mainly affected by the epidemic, the company's iHealth kit products are in the strong market demand in the United States, and the company actively takes various measures to achieve the effective operation of production and supply chain, continues to do a good job in order fulfillment and market development, and ensures the timely delivery of customer orders, and its performance has increased
significantly compared with the same period last year.
In addition, the US dollar continued to rise, and the company's foreign exchange income increased
compared with the same period last year.
3 billion yuan, a year-on-year increase of 31818.
29% ~ 32416.
76%, only 50.
13 million yuan
in the same period last year.
Jiuan Medical said that mainly affected by the epidemic, the company's iHealth kit products are in the strong market demand in the United States, and the company actively takes various measures to achieve the effective operation of production and supply chain, continues to do a good job in order fulfillment and market development, and ensures the timely delivery of customer orders, and its performance has increased
significantly compared with the same period last year.
In addition, the US dollar continued to rise, and the company's foreign exchange income increased
compared with the same period last year.
For the soaring performance, at the company's first-half performance briefing, investors have paid attention to its third-quarter performance, future strategic layout, etc.
, and the number of questions exceeded 100
。 The company responded that it will continue to accelerate the implementation of the explosive product strategy and the new model of diabetes diagnosis and treatment "O+O" in China and the United States, on the one hand, make full use of the brand advantage formed by the best-selling iHealth forehead thermometer and kit in the United States in recent years, in terms of kits, the product still has continuous market demand, the company will focus on the North American market at the same time, choose countries with high access requirements to apply for registration
。 In addition, it will tap market demand and promote China's competitive technologies and products to the US market; Increase investment in the field of Internet medicine, and plan to open nearly 600 "common care" centers in hospitals in many cities and regions across the country in the next 3-4 years to serve more diabetic patients
.
, and the number of questions exceeded 100
。 The company responded that it will continue to accelerate the implementation of the explosive product strategy and the new model of diabetes diagnosis and treatment "O+O" in China and the United States, on the one hand, make full use of the brand advantage formed by the best-selling iHealth forehead thermometer and kit in the United States in recent years, in terms of kits, the product still has continuous market demand, the company will focus on the North American market at the same time, choose countries with high access requirements to apply for registration
。 In addition, it will tap market demand and promote China's competitive technologies and products to the US market; Increase investment in the field of Internet medicine, and plan to open nearly 600 "common care" centers in hospitals in many cities and regions across the country in the next 3-4 years to serve more diabetic patients
.
WuXi AppTec net profit: 6.
772 billion yuanYear-on-year increase: 77.
92%
772 billion yuanYear-on-year increase: 77.
92%
WuXi AppTec, as a leading CXO company, has always attracted market attention, and a few days ago, the company disclosed its first three quarters of performance forecast, with revenue of 28.
395 billion yuan, a year-on-year increase of 71.
87%; The net profit was 6.
772 billion yuan, a year-on-year increase of 77.
92%.
Among them, in terms of main business, the company continues to strengthen the integrated CRDMO (contract research, development and production) and CTDMO (contract testing, research and development and production) business models, under the influence of the continuous and repeated epidemics in many places, give full play to the advantages of global layout, multi-location operation and full industry chain coverage, timely formulate and implement business continuity plans, and ensure that the company completes the overall performance goals
.
In addition, the company is confident in achieving the target of 68~72% revenue growth in 2022
.
It is worth noting that WuXi AppTec's revenue in the first half of 2022 was 17.
756 billion yuan, which means that the company's revenue in the third quarter alone exceeded 10 billion
.
395 billion yuan, a year-on-year increase of 71.
87%; The net profit was 6.
772 billion yuan, a year-on-year increase of 77.
92%.
Among them, in terms of main business, the company continues to strengthen the integrated CRDMO (contract research, development and production) and CTDMO (contract testing, research and development and production) business models, under the influence of the continuous and repeated epidemics in many places, give full play to the advantages of global layout, multi-location operation and full industry chain coverage, timely formulate and implement business continuity plans, and ensure that the company completes the overall performance goals
.
In addition, the company is confident in achieving the target of 68~72% revenue growth in 2022
.
It is worth noting that WuXi AppTec's revenue in the first half of 2022 was 17.
756 billion yuan, which means that the company's revenue in the third quarter alone exceeded 10 billion
.
Brokerage analysis pointed out that the CXO track is highly prosperous, and WuXi AppTec's "integrated and end-to-end" strategy is expected to consolidate competitive barriers and drive the company's long-term rapid growth
.
It is expected that WuXi AppTec's revenue from 2022 to 2024 will be 36.
817 billion yuan, 44.
073 billion yuan and 54.
283 billion yuan, a year-on-year increase of 60.
75%, 19.
71% and 23.
17%, and the net profit will be 8.
485 billion yuan, 9.
891 billion yuan and 12.
892 billion yuan, a year-on-year increase of 66.
46%, 16.
57% and 30.
34%.
.
It is expected that WuXi AppTec's revenue from 2022 to 2024 will be 36.
817 billion yuan, 44.
073 billion yuan and 54.
283 billion yuan, a year-on-year increase of 60.
75%, 19.
71% and 23.
17%, and the net profit will be 8.
485 billion yuan, 9.
891 billion yuan and 12.
892 billion yuan, a year-on-year increase of 66.
46%, 16.
57% and 30.
34%.
Scale up faster! The performance of the common people, Da Shenlin and Yifeng has steadily climbed
It is worth noting that the performance of listed chains has risen steadily in the first three quarters, and the net profit growth rate of Laobai, Da Shenlin and Yifeng Pharmacy has exceeded 10%.
With the support of favorable policies, listed chains have increased their expansion efforts this year, and the scale and chaining rate have continued to increase
.
With the support of favorable policies, listed chains have increased their expansion efforts this year, and the scale and chaining rate have continued to increase
.
People's net profit: 609 million yuan year-on-year increase: 14.
34%
34%
The people's performance report for the first three quarters showed that the revenue was 13.
776 billion yuan, a year-on-year increase of 22.
1%; The net profit was 609 million yuan, a year-on-year increase of 14.
34%.
The steady growth of the people's performance is mainly due to the further improvement of the company's operating scale and management quality, the gradual emergence of efficient organizational changes and digital transformation results, and the good integration of
Hunan people's Huairen pharmacy chain.
776 billion yuan, a year-on-year increase of 22.
1%; The net profit was 609 million yuan, a year-on-year increase of 14.
34%.
The steady growth of the people's performance is mainly due to the further improvement of the company's operating scale and management quality, the gradual emergence of efficient organizational changes and digital transformation results, and the good integration of
Hunan people's Huairen pharmacy chain.
Net profit: 921 million ~ 930 million yuan Year-on-year increase: 12.
6% ~ 13.
65%
6% ~ 13.
65%
Da Shenlin expects a net profit of 921 million ~ 930 million yuan in the first three quarters, a year-on-year increase of 12.
60% ~ 13.
65%.
Da Shenlin said that the performance growth benefited from policy support such as volume procurement, dual-channel stores, and prescription outflow, and the market expansion of the pharmaceutical retail industry continued to expand and the industry concentration accelerated
.
According to the changes in the consumer market, epidemic prevention and control policies and other factors, the company adopts a variety of business strategies to actively respond, and makes reasonable use of the three modes of self-construction, mergers and acquisitions and direct franchise to steadily promote the regional expansion of stores, with stable overall revenue growth, effective control of operating costs, gradual improvement of management efficiency, and further reflection of
scale effect.
60% ~ 13.
65%.
Da Shenlin said that the performance growth benefited from policy support such as volume procurement, dual-channel stores, and prescription outflow, and the market expansion of the pharmaceutical retail industry continued to expand and the industry concentration accelerated
.
According to the changes in the consumer market, epidemic prevention and control policies and other factors, the company adopts a variety of business strategies to actively respond, and makes reasonable use of the three modes of self-construction, mergers and acquisitions and direct franchise to steadily promote the regional expansion of stores, with stable overall revenue growth, effective control of operating costs, gradual improvement of management efficiency, and further reflection of
scale effect.
Yifeng Pharmacy net profit: 815 million ~ 825 million yuan year-on-year increase: 17.
11% ~ 18.
54%
11% ~ 18.
54%
Yifeng Pharmacy expects revenue of 13.
240 billion ~ 13.
420 billion yuan in the first three quarters, a year-on-year increase of 21.
05% ~ 22.
69%; The net profit was 815 million ~ 825 million yuan, a year-on-year increase of 17.
11% ~ 18.
54%.
Yifeng Pharmacy said that with the normalization of the epidemic and the precision of government prevention and control measures, drug retail has become a rigid need for people's livelihood, and the industry's operation has gradually improved; At the same time, under the background of continuous standardization of industry policies and separation of medicine, the scale of the pharmaceutical retail industry continues to expand, and the overall operation of the industry continues to improve
.
In the first three quarters, the company continued to adhere to the expansion model of "new opening + mergers and acquisitions + joining" and regional focus, the store network was continuously improved, and the number of stores continued to grow
rapidly.
With the continuous optimization of the company's operation system and the continuous improvement of digital management level, the store operation efficiency continues to improve
year-on-year.
240 billion ~ 13.
420 billion yuan in the first three quarters, a year-on-year increase of 21.
05% ~ 22.
69%; The net profit was 815 million ~ 825 million yuan, a year-on-year increase of 17.
11% ~ 18.
54%.
Yifeng Pharmacy said that with the normalization of the epidemic and the precision of government prevention and control measures, drug retail has become a rigid need for people's livelihood, and the industry's operation has gradually improved; At the same time, under the background of continuous standardization of industry policies and separation of medicine, the scale of the pharmaceutical retail industry continues to expand, and the overall operation of the industry continues to improve
.
In the first three quarters, the company continued to adhere to the expansion model of "new opening + mergers and acquisitions + joining" and regional focus, the store network was continuously improved, and the number of stores continued to grow
rapidly.
With the continuous optimization of the company's operation system and the continuous improvement of digital management level, the store operation efficiency continues to improve
year-on-year.
Institutions "watched" the third quarterly report, and pharmaceutical stocks were on fire again
Recently, pharmaceutical stocks have ushered in a long-lost "great counteroffensive", Hengrui Pharmaceutical, Huason Pharmaceutical, Shuangcheng Pharmaceutical, etc.
have risen one after another, and Taiji Group, Sunflower Pharmaceutical, Renfu Pharmaceutical, etc.
have risen
sharply.
On the whole, the policy side is favorable to release positive signals, valuations are at historically low levels, and the third quarterly report has entered an intensive disclosure period, or the main reasons for the recent rebound, at the same time, more and more institutions are also "watching" the pharmaceutical sector
.
have risen one after another, and Taiji Group, Sunflower Pharmaceutical, Renfu Pharmaceutical, etc.
have risen
sharply.
On the whole, the policy side is favorable to release positive signals, valuations are at historically low levels, and the third quarterly report has entered an intensive disclosure period, or the main reasons for the recent rebound, at the same time, more and more institutions are also "watching" the pharmaceutical sector
.
Pharmaceutical stocks surveyed by institutions since October
In the survey, China Resources Sanjiu was asked about the sales of CHC and prescription drugs in the third quarter, the proportion of online business, the company's positioning in China Resources Group, etc.
, China Resources Sanjiu said that the company's business area is positioned as CHC health consumer goods and prescription drug business, CHC as the company's core business, Sinopharm business (formula granules + pieces) and prescription drugs as development business.
.
.
Since October, many institutions have accelerated the pace of investigation of pharmaceutical stocks, including leaders in Kelun Pharmaceutical, China Resources Sanjiu, Jingxin Pharmaceutical and other segments
.
From the perspective of institutional types, it covers securities research institutes, investment companies, fund management companies, etc
.
, China Resources Sanjiu said that the company's business area is positioned as CHC health consumer goods and prescription drug business, CHC as the company's core business, Sinopharm business (formula granules + pieces) and prescription drugs as development business.
.
.
Since October, many institutions have accelerated the pace of investigation of pharmaceutical stocks, including leaders in Kelun Pharmaceutical, China Resources Sanjiu, Jingxin Pharmaceutical and other segments
.
From the perspective of institutional types, it covers securities research institutes, investment companies, fund management companies, etc
.
In December last year, the Shenzhen Stock Exchange pointed out in its revision of the stock listing rules that it is no longer mandatory for companies to disclose quarterly performance forecasts
.
From the perspective of the number of announcements, it decreased by more than 30%
year-on-year.
It is worth mentioning that although some pharmaceutical companies have not released performance forecasts, they have disclosed the main operating data in the first three quarters and three quarters of 2022, and the performance forecast also highlights the company's confidence in development, and the institution has given a buy and overweight rating
.
The risk of the pharmaceutical sector is released centrally, and as the normalization of epidemic prevention and control gradually becomes clear, the third quarter performance is expected to achieve accelerated growth
.
Source: Oriental Wealth Network, company announcements, etc.
Note: Data statistics as of the close of October 20, if there are any omissions, welcome to correct!
.
From the perspective of the number of announcements, it decreased by more than 30%
year-on-year.
It is worth mentioning that although some pharmaceutical companies have not released performance forecasts, they have disclosed the main operating data in the first three quarters and three quarters of 2022, and the performance forecast also highlights the company's confidence in development, and the institution has given a buy and overweight rating
.
The risk of the pharmaceutical sector is released centrally, and as the normalization of epidemic prevention and control gradually becomes clear, the third quarter performance is expected to achieve accelerated growth
.
Source: Oriental Wealth Network, company announcements, etc.
Note: Data statistics as of the close of October 20, if there are any omissions, welcome to correct!
